Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.06
NAS:AMRI's Cash-to-Debt is ranked lower than
98% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. NAS:AMRI: 0.06 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:AMRI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.06  Med: 4.89 Max: No Debt
Current: 0.06
Equity-to-Asset 0.26
NAS:AMRI's Equity-to-Asset is ranked lower than
87% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NAS:AMRI: 0.26 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:AMRI' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.25  Med: 0.8 Max: 0.96
Current: 0.26
0.25
0.96
Piotroski F-Score: 3
Altman Z-Score: 1.37
Beneish M-Score: -2.46
WACC vs ROIC
6.43%
0.57%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % -1.99
NAS:AMRI's Operating Margin % is ranked higher than
69% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. NAS:AMRI: -1.99 )
Ranked among companies with meaningful Operating Margin % only.
NAS:AMRI' s Operating Margin % Range Over the Past 10 Years
Min: -36.43  Med: 1.19 Max: 11.32
Current: -1.99
-36.43
11.32
Net Margin % -11.26
NAS:AMRI's Net Margin % is ranked higher than
65% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. NAS:AMRI: -11.26 )
Ranked among companies with meaningful Net Margin % only.
NAS:AMRI' s Net Margin % Range Over the Past 10 Years
Min: -31.74  Med: -1.43 Max: 8.97
Current: -11.26
-31.74
8.97
ROE % -23.86
NAS:AMRI's ROE % is ranked higher than
58% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. NAS:AMRI: -23.86 )
Ranked among companies with meaningful ROE % only.
NAS:AMRI' s ROE % Range Over the Past 10 Years
Min: -23.94  Med: -1.59 Max: 6.22
Current: -23.86
-23.94
6.22
ROA % -6.71
NAS:AMRI's ROA % is ranked higher than
70% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. NAS:AMRI: -6.71 )
Ranked among companies with meaningful ROA % only.
NAS:AMRI' s ROA % Range Over the Past 10 Years
Min: -17.99  Med: -1.06 Max: 5.29
Current: -6.71
-17.99
5.29
ROC (Joel Greenblatt) % -2.35
NAS:AMRI's ROC (Joel Greenblatt) % is ranked higher than
74% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. NAS:AMRI: -2.35 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:AMRI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -35.59  Med: 1.43 Max: 13.51
Current: -2.35
-35.59
13.51
3-Year Revenue Growth Rate 24.40
NAS:AMRI's 3-Year Revenue Growth Rate is ranked higher than
77% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. NAS:AMRI: 24.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:AMRI' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -1.6  Med: 8.5 Max: 78
Current: 24.4
-1.6
78
3-Year EBITDA Growth Rate -10.40
NAS:AMRI's 3-Year EBITDA Growth Rate is ranked lower than
64% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. NAS:AMRI: -10.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:AMRI' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -48.6  Med: 9.65 Max: 60.9
Current: -10.4
-48.6
60.9
GuruFocus has detected 8 Warning Signs with Albany Molecular Research Inc $NAS:AMRI.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:AMRI's 30-Y Financials

Financials (Next Earnings Date: 2017-11-08 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

AMRI Guru Trades in Q3 2016

Jim Simons 347,242 sh (+194.42%)
Paul Tudor Jones 14,744 sh (+17.95%)
Chuck Royce 1,254,296 sh (+5.94%)
Murray Stahl 56,000 sh (unchged)
Ken Fisher 157,794 sh (-22.44%)
» More
Q4 2016

AMRI Guru Trades in Q4 2016

Jim Simons 357,900 sh (+3.07%)
Chuck Royce 1,290,911 sh (+2.92%)
Murray Stahl 56,000 sh (unchged)
Paul Tudor Jones Sold Out
Ken Fisher 80,589 sh (-48.93%)
» More
Q1 2017

AMRI Guru Trades in Q1 2017

Paul Tudor Jones 16,300 sh (New)
Ken Fisher 144,417 sh (+79.20%)
Chuck Royce 1,518,276 sh (+17.61%)
Murray Stahl 56,000 sh (unchged)
Jim Simons 148,342 sh (-58.55%)
» More
Q2 2017

AMRI Guru Trades in Q2 2017

Ken Fisher 184,589 sh (+27.82%)
» More
» Details

Insider Trades

Latest Guru Trades with AMRI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 541711    SIC: 8731
Compare:NAS:OMER, NAS:BYSI, NAS:ACOR, NAS:ADRO, NYSE:BHVN, NAS:INSY, NAS:EPZM, NAS:KERX, NAS:AKAO, NAS:IMMU, NAS:FPRX, NAS:SGMO, NAS:ZIOP, NAS:INSM, NAS:PTCT, NAS:AIMT, NAS:ARNA, NAS:XNCR, NAS:ESPR, NAS:ACRS » details
Traded in other countries:AYM.Germany,
Headquarter Location:USA
Albany Molecular Research Inc is a contract research and manufacturing company, providing customers drug discovery, development and manufacturing services.

Albany Molecular Research provides research services to pharmaceutical, biotechnology, and chemical companies. The company offers services like design and modification of potential lead compounds, purification technique development, quality control, bulk ingredient stability studies, and regulatory documentation preparation. The company has entered into collaborative agreements with companies like Eli Lilly and Cambrex. Albany's acquisition of Organichem provided the company with commercial manufacturing capabilities.

Ratios

vs
industry
vs
history
Forward PE Ratio 19.38
AMRI's Forward PE Ratio is ranked higher than
56% of the 62 Companies
in the Global Biotechnology industry.

( Industry Median: 21.98 vs. AMRI: 19.38 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 3.14
AMRI's PB Ratio is ranked higher than
59% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. AMRI: 3.14 )
Ranked among companies with meaningful PB Ratio only.
AMRI' s PB Ratio Range Over the Past 10 Years
Min: 0.29  Med: 1.29 Max: 3.14
Current: 3.14
0.29
3.14
PS Ratio 1.40
AMRI's PS Ratio is ranked higher than
93% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. AMRI: 1.40 )
Ranked among companies with meaningful PS Ratio only.
AMRI' s PS Ratio Range Over the Past 10 Years
Min: 0.31  Med: 1.37 Max: 2.93
Current: 1.4
0.31
2.93
Price-to-Operating-Cash-Flow 101.40
AMRI's Price-to-Operating-Cash-Flow is ranked lower than
89% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 25.11 vs. AMRI: 101.40 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
AMRI' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.92  Med: 16.02 Max: 314.81
Current: 101.4
4.92
314.81
EV-to-EBIT -133.44
AMRI's EV-to-EBIT is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. AMRI: -133.44 )
Ranked among companies with meaningful EV-to-EBIT only.
AMRI' s EV-to-EBIT Range Over the Past 10 Years
Min: -133.44  Med: 19.15 Max: 455
Current: -133.44
-133.44
455
EV-to-EBITDA 32.45
AMRI's EV-to-EBITDA is ranked lower than
68% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. AMRI: 32.45 )
Ranked among companies with meaningful EV-to-EBITDA only.
AMRI' s EV-to-EBITDA Range Over the Past 10 Years
Min: -41.7  Med: 10.1 Max: 49.2
Current: 32.45
-41.7
49.2
Current Ratio 2.31
AMRI's Current Ratio is ranked lower than
71% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. AMRI: 2.31 )
Ranked among companies with meaningful Current Ratio only.
AMRI' s Current Ratio Range Over the Past 10 Years
Min: 2.21  Med: 5.41 Max: 17.83
Current: 2.31
2.21
17.83
Quick Ratio 1.26
AMRI's Quick Ratio is ranked lower than
80% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. AMRI: 1.26 )
Ranked among companies with meaningful Quick Ratio only.
AMRI' s Quick Ratio Range Over the Past 10 Years
Min: 1.11  Med: 4.56 Max: 17.25
Current: 1.26
1.11
17.25
Days Inventory 110.82
AMRI's Days Inventory is ranked higher than
58% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 131.43 vs. AMRI: 110.82 )
Ranked among companies with meaningful Days Inventory only.
AMRI' s Days Inventory Range Over the Past 10 Years
Min: 57.53  Med: 63.97 Max: 110.82
Current: 110.82
57.53
110.82
Days Sales Outstanding 81.11
AMRI's Days Sales Outstanding is ranked lower than
60% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. AMRI: 81.11 )
Ranked among companies with meaningful Days Sales Outstanding only.
AMRI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 43.89  Med: 64.89 Max: 100.17
Current: 81.11
43.89
100.17

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -10.70
AMRI's 3-Year Average Share Buyback Ratio is ranked higher than
53% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. AMRI: -10.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AMRI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -10.7  Med: -0.6 Max: 2.8
Current: -10.7
-10.7
2.8

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 4.42
AMRI's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
61% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 3.53 vs. AMRI: 4.42 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
AMRI' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.4  Med: 0.89 Max: 4.42
Current: 4.42
0.4
4.42
Price-to-Median-PS-Value 1.02
AMRI's Price-to-Median-PS-Value is ranked lower than
55% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. AMRI: 1.02 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AMRI' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.28  Med: 1.38 Max: 37.97
Current: 1.02
0.28
37.97
Earnings Yield (Greenblatt) % -0.75
AMRI's Earnings Yield (Greenblatt) % is ranked higher than
70% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. AMRI: -0.75 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AMRI' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -108.3  Med: 1.2 Max: 16.5
Current: -0.75
-108.3
16.5
Forward Rate of Return (Yacktman) % 17.62
AMRI's Forward Rate of Return (Yacktman) % is ranked higher than
55% of the 129 Companies
in the Global Biotechnology industry.

( Industry Median: 14.33 vs. AMRI: 17.62 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
AMRI' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -16.9  Med: 0.8 Max: 21.4
Current: 17.62
-16.9
21.4

More Statistics

Revenue (TTM) (Mil) $628.69
EPS (TTM) $ -1.78
Beta0.63
Short Percentage of Float25.16%
52-Week Range $13.01 - 22.17
Shares Outstanding (Mil)42.96

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 722 780
EPS ($) 1.12 1.50
EPS without NRI ($) 1.12 1.50
EPS Growth Rate
(Future 3Y To 5Y Estimate)
15.00%
Dividends per Share ($)
» More Articles for AMRI

Headlines

Articles On GuruFocus.com
The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement on Behalf of Purchasers of Commo Jul 17 2017 
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Albany Molecular Re Jul 13 2017 
WeissLaw LLP: The Proposed Acquisition of Albany Molecular Research Inc. May Not Be In the Best Inte Jun 09 2017 
Harwood Feffer LLP Announces Investigation of Albany Molecular Research, Inc. Jun 07 2017 
ALBANY MOLECULAR INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Jun 06 2017 
Albany Molecular (AMRI) Alert: J&W Investigates Price and Process of Proposed Sale of Albany Molecul Jun 06 2017 
AMRI Signs Definitive Agreement To Be Acquired By The Carlyle Group and GTCR for $21.75 per share in Jun 06 2017 
AMRI to Present at Jefferies Healthcare Conference Jun 02 2017 
AMRI Receives NIH Contract Award for Drug Substance Development and Manufacturing Services May 02 2017 
SSCI Receives a 2017 Biotechnology Award for Global Research and Manufacturing Apr 26 2017 

More From Other Websites
Albany Molecular Research, Inc. -- Moody's assigns B3 CFR to UIC Merger Sub, Inc. (dba Albany... Jul 19 2017
The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement on Behalf of Purchasers of... Jul 17 2017
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Albany Molecular... Jul 13 2017
SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Albany Molecular... Jul 05 2017
Lifshitz & Miller LLP Announces Investigation of Albany Molecular Research, Inc., Atwood Oceanics,... Jul 03 2017
AMRI Announces Early Termination of HSR Waiting Period for The Carlyle Group and GTCR's Proposed... Jun 29 2017
EQUITY ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Whether the... Jun 20 2017
SHAREHOLDER UPDATE: Brodsky & Smith, LLC Announces an Investigation of Albany Molecular Research,... Jun 15 2017
INVESTOR ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Albany Molecular... Jun 13 2017
The Law Offices of Vincent Wong Reminds Investors of an Investigation of Albany Molecular Research,... Jun 13 2017
Edited Transcript of AMRI earnings conference call or presentation 9-May-17 12:30pm GMT Jun 12 2017
SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Albany Molecular Research,... Jun 09 2017
The Law Offices of Vincent Wong Notifies Investors of an Investigation of Albany Molecular Research,... Jun 09 2017
WeissLaw LLP: The Proposed Acquisition of Albany Molecular Research Inc. May Not Be In the Best... Jun 09 2017
ETFs with exposure to Albany Molecular Research, Inc. : June 8, 2017 Jun 08 2017
Harwood Feffer LLP Announces Investigation of Albany Molecular Research, Inc. Jun 07 2017
SHAREHOLDER ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Albany... Jun 07 2017
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Concerning Whether the... Jun 07 2017
Albany Molecular Research, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe Investigates... Jun 07 2017
Albany Molecular Research, Inc. -- Moody's places Albany Molecular's ratings on review for downgrade Jun 07 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}